Understanding AML remission, relapse, and refractory disease
Fact-checked by Acute myeloid leukemia (AML) evolves over time based on how the disease responds to treatment. AML remission, relapse, and refractory disease are key concepts that help define disease status and inform treatment options at every stage of this blood cancer.
In AML, immature blood cells called blasts grow out of control and crowd out healthy blood cells in the bone marrow. The goal of treatment is to eliminate these abnormal cells.
Key terms at a glance
Clinicians use the terms remission, relapse, refractory, and measurable residual disease across many cancers and other diseases to describe a patient’s cancer status after treatment. In AML, their definitions are:
Scroll horizontally to view all columns -->
| Term | Definition |
|---|---|
| Remission | When signs and symptoms of AML have decreased fully or partially |
| Measurable residual disease (MRD) | The small number of cancerous cells that remain in the body after treatment |
| Relapse | When AML returns after a period of remission |
| Refractory | AML that doesn’t enter remission after treatment |
What does remission mean in AML?
Patients reach AML remission when signs and symptoms of their cancer decrease after treatment, resolving fully or partially. To determine remission status, doctors look for:
- reductions in cancerous blast cells in the bone marrow
- restoration of healthy blood cell counts
- absence of disease spread beyond the blood and bone marrow
- freedom from regular red blood cell transfusions
The degree of response determines the specific type of AML remission:
- Complete remission: Standard tests show no signs of remaining cancer after treatment. The bone marrow contains fewer than 5% blasts, healthy blood cell counts have recovered, blood transfusions are not needed, and the cancer has not formed tumors outside the bone marrow.
- Complete remission with incomplete hematologic recovery: Bone marrow blasts drop below 5%, though other blood counts have not fully recovered.
- Partial remission: The number of blasts in bone marrow has decreased significantly, but is still above the 5% threshold.
Complete AML remission is the primary treatment goal, but other forms of remission can indicate a positive response. Patients in partial remission may require additional treatments to achieve complete remission.
Around two-thirds of people with AML go into complete remission after initial chemotherapy, though the chances of remission vary by factors such as age and overall health.
What is measurable residual disease?
Measurable residual disease (MRD) refers to the small number of cancer cells that survive initial treatment. Because standard tests cannot detect these cells, doctors use highly sensitive advanced techniques, including genetic sequencing, to classify a patient’s status as:
- MRD negative (undetectable): no leukemia cells found
- MRD positive: some leukemia cells detected
MRD status does not dictate whether someone has achieved remission. Patients enter complete remission by meeting all criteria on standard tests, even if they test MRD positive. Instead, MRD testing helps predict the durability of a person’s remission. Generally, MRD negativity correlates with longer periods of remission, whereas MRD positivity increases the risk of a future relapse, though this is not always the case.
Doctors routinely test for MRD, especially during early remission, to estimate relapse risk and intervene early if leukemia becomes detectable again.
Does remission mean AML is cured?
AML remission does not necessarily mean the disease is cured, as cancer can still return. Predicting how long AML remission will last remains difficult for individual cases.
However, it is possible for AML to be cured. For most people, a stem cell transplant offers the main curative treatment option. A person who has been in complete remission for five years has a very low risk of AML recurrence.
How do doctors monitor for AML after treatment?
After treatment, care teams closely monitor patients to assess how the body responds. Follow-up includes clinical examinations, symptom reviews, and blood and bone marrow tests to look for signs of cancer or predict relapse risk.
The frequency of follow-up appointments varies depending on individual needs, but they occur most frequently in the first two years after treatment, when the risk of a relapse is highest.
What is relapsed or recurrent AML?
Relapsed AML, also called recurrent AML, describes the return of cancer activity after a period of remission. Most AML relapses occur within the first two years of reaching remission and become very rare after five years.
Possible signs of an AML relapse include:
- elevated leukemia cells in the blood or bone marrow
- reduced healthy blood cells in the blood or bone marrow
- new or worsening AML symptoms
Regular monitoring helps identify early signs before AML relapse symptoms become obvious.
Up to half of the people who achieve AML remission will eventually experience a relapse, with overall odds depending heavily on factors such as age and health.
What is refractory AML?
Refractory AML refers to a form of the disease that does not respond to initial treatment.
The exact definition of refractory disease varies by treatment intensity. For high-intensity initial treatment (induction therapy), this usually means failing to achieve remission after at least two courses. With lower intensity treatments, the threshold varies depending on the specific regimen.
AML not responding to treatment may require alternative or advanced therapeutic approaches to achieve remission.
Why AML may not respond or may return
An AML relapse often suggests that some cancerous cells survived treatment and began to multiply again. This survival occurs when cells possess genetic changes that make them more resistant to treatment, or when cells develop these mutations later on.
Treatment-resistant genetic mutations are also associated with refractory AML, though other factors like age and general health may influence treatment response.
Treatment after relapse or refractory AML
Several factors guide the development of a new treatment plan for relapsed or refractory AML, including:
- previous treatments and responses
- duration of prior remission periods
- age and general health
- genetic and molecular features of the cancer cells
- patient preferences
Depending on the situation, AML relapse treatment may include previously successful treatments or introduce new ones. Refractory AML usually requires a different treatment approach altogether.
In some cases, participation in a clinical trial offers access to promising experimental treatments not yet commercially available.
Coping with uncertainty and getting support
Because AML remission, relapse, and refractory disease are difficult to predict, patients and caregivers often face significant uncertainty and stress.
Mental healthcare and community support groups help individuals build healthy coping strategies. Several organizations offer support groups and resources for people living with AML and other forms of blood cancer:
Many cancer treatment centers also employ social workers who offer support groups and care resources for patients and caregivers.
Rare Cancer News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
